Viral Haemorrhagic Fevers

exp date isn't null, but text field is

Ebola and Marburg

Ebola and Marburg are severe zoonotic multisystem febrile diseases caused by RNA viruses. They are notifiable diseases.

Cause

  • Ebola and Marburg viruses. Transmission to humans happens through contact with meat or body fluids of an infected animal. The disease can then be transmitted from human to human through body fluids (including semen for months after recovery) and it is highly contagious.

Risk factors

  • Communities around game parks
  • Communities in endemic area
  • Cultural practices like burial rituals
  • Poor infection control policies
  • History of exposure to infected people in the last 2 to 21 days i.e sexual partner, breastfeeding mothers
  • Recent contact with infected animals e.g monkeys, bats, infected game meat

Clinical features

  • Early signs (non specific): sudden fever, weakness, headache, muscle pains, loss of appetite, conjunctivitis
  • Late signs:
    • Diarrhoea (watery or bloody), vomiting
    • Mucosal and gastrointestinal bleeding: chest pain, respiratory distress, circulatory shock
    • CNS dysfunction, confusion, seizures
    • Miscarriage in pregnancy
    • Elevated AST and ALT, kidney injury, electrolyte abnormalities

Note: Haemorrhage is seen in less than a third of Ebola patients

Differential diagnosis

  • Malaria, rickettsiosis, meningitis
  • Shigellosis, typhoid
  • Anthrax, sepsis, viral hepatitis, dengue, leptospirosis

Investigations

  • Send blood sample to a referral laboratory for specific testing (taking off blood samples from patients suspected of viral hemorrhagic fever should be done by a trained healthcare worker in appropriate PPE.

  • Notify district surveillance focal person

Management

Treatment LOC
  • Refer all patients to regional referral hospital for management in an appropriate setting
  • Notify the district health team
RR

 

Safety of health workers: maximum level of infection control procedures

Health workers should maintain a high level of suspicion for Ebola virus disease. While standard precautions should be followed for all patients at all times, implementation of transmission-based precautions for cases suspected or confirmed to have Ebola or Marburg virus diseases is essential. This includes: screening for rapid identification and isolation of cases.

Hand hygiene according to the WHO 5 moments safe injection practices use of personal protective equipment (e.g. eye protec- tion, mask (medical or respirator), gloves, gown or coverall, head covering, apron and gum (rubber) boots.

Handling and disposing of all waste related to the care of an Ebola patients as infectious

Safe handling and disinfection of linens (or disposal if not possible) and thorough cleaning and disinfection of the environment and medical equipment.

Disinfectants (e.g. chlorine mixture of 0.5% for surfaces) used must be prepared and used ensuring adequate concentration and contact time on surfaces.

Handling of the deceased is particularly high risk and should be kept to a minimum. Strict adherence to IPC measures including hand hygiene, use of personal protective equipment (e.g. eye protection, mask (medical or respirator), gloves, gown or coverall, head covering, apron and gum (rubber) boots is required.

Patient care

  • Refer to the MoH recent guidelines for management of viral hemorrrhagic fevers
  • Optimised supportive treatment of signs and symptoms
  • Replace and monitor fluids and electrolytes for patients with diarrhoea or vomiting

Triage and contact tracing

  • Triage patient (those who had contact with a patient or not)
  • Contact identification, contact listing and contact follow up

Dead Body handling

  • Avoid washing or touching the dead
  • There should be no gathering at funerals
  • The dead should be buried promptly by a designated burial team

Prevention

  • Health education of the population (e.g. avoid eating wild animals)
  • Effective outbreak communication and having haemorrhagic viral fever protocols in place
  • Appropriate safety gear for patients/health workers in suspect cases
  • Modification of burial practices
  • Use of condoms

Yellow Fever

An acute viral haemorrhagic fever transmitted through the bite of infected female Aedes aegypti mosquito. Incubation period is 3 to 6 days. It is a notifiable disease.

Cause

  • Yellow fever RNA virus

Risk factors

  • Residents in endemic area
  • Hunters and settlers around game parks

Clinical Features

First stage:

  • Fever, chills, headache, backache, muscle pain, prostration, nausea, vomiting, fatigue. Usually resolves within 3-4 days.

Second stage:

  • About 15% of cases enter into a second or toxic stage after 1-2 day of remission: high fever, prostration, signs and symptoms of hepatic failure, renal failure and bleeding (jaundice, nose bleeding, gingival bleeding, vomiting blood, blood in stool)
  • About half of these patients die within 7-10 days

Differential diagnosis

  • Hepatitis E, liver failure
  • Malaria, Ebola

Investigations

  • PCR in early phases
  • ELISA in the late stage

Management

Treatment LOC
  • Refer all cases to regional referral hospital
  • Notify the district health team
  • There is no specific antiviral drug treatment
  • Supportive treatment is recommended:
    • Rehydration
    • Management of liver and kidney failure
    • Antipyretics for fever
    • Blood transfusion
  • Treat associated bacterial infections with antibiotics 
RR

 

Note: Individuals who have recovered from a yellow fever infection develop life-long immunity 

Prevention

  • Vaccination (see Immunizations)
  • Elimination of mosquito breeding sites
  • Epidemic preparedness i.e prompt detection and treatment

Covid-19 Diseases

Coronavirus disease (COVID-19) results from infection with the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). It is a novel virus in humans, knowledge of which and its pathogenesis still evolving. Additionally, the population-level immunity is uncertain. Complications of the severe infection can result in death.

Clinical features

Early symptoms are non-specific and may include:

fever, cough, myalgia, fatigue, shortness of breath, sore throat, headache, flu-like symptoms, diarrhea, nausea, respiratory distress, features of renal failure, pericarditis, and Disseminated Intravascular Coagulation (DIC).

It is important to know that many individuals with COVID-19 are asymptomatic. It is therefore paramount that all health workers observe strict infection prevention and control (IPC) measures at all times.

Classification of COVID 19 Disease

Disease Stage

Hallmark

Features

Mild Disease

No Respiratory Distress

Normal Vital Signs

Moderate Disease

Non-Severe Pneumonia

Crackles in chest but Normal SPO2,

mild respiratory distress (Resp Rate <30)

Severe Disease

Oxygen

De saturation

Severe Respiratory distress (Resp Rate >30) & SPO2 <90%,

Critical

Organ Dysfunction

CNS: Altered Mental State

CVS: Hypotension & Shock

Kidney: Decreased Urine Output, Raised Creatinine

Liver: Elevated liver enzymes

Coagulation: Raised PT & INR, Thrombocytopenia

Endocrine: Hypoglycemia

 

 

 

Groups at High Risk of Developing Severe Disease or Complications

  • Age > 65 year
  • Obesity
  • Lung diseases (e.g. asthma, TB, COPD)
  • Hypertension
  • Heart conditions such as history of heart attack or stroke
  • Diabetes
  • Cancer patients whether or not on chemotherapy
  • Advanced liver disease
  • Person living with HIV
  • Kidney disease
  • Severe Acute Malnutrition
  • Sickle cell disease
  • COVID 19 unvaccinated
  • Pregnancy and recent pregnancy
  • Hypertension

Differential diagnoses

Malaria and other febrile illnesses.

Common respiratory, infectious, cardiovascular, oncological, and gastrointestinal diseases

Investigations

Management

Perform SARS-CoV-2 Rapid Diagnostic Test (RDT)

Carry out nasopharyngeal swabs for RT-RNA test

COVID-19 screening and triage process at health facilities
  • COVID-19 triage aims to flag suspected patients at first point of contact within the healthcare system in order to protect other patients and staff from potential exposure.
  • Identify and rapidly address severe symptoms, rule out other conditions with features similar to COVID-19, ascertain if suspect case definition is met.
  • All suspected patients should be directed to a designated area away from other patients and handled as per standard Covid protection guidelines
  • Refer to the Comprehensive COVID-19 Case Management Guidelines for details.
Treatment LOC

Safety of health workers and caregivers: maximum level of infection control procedures

  • Strict isolation of suspect cases Use of adequate protective gear Minimize invasive intervention Safe handling of linen
  • Appropriate use of chlorine mixtures Proper disposal of health care waste
  • Educate the patient and care givers on appropriate infection control measures
HC2

No Hospitalization (mild to moderate diseases)

HC2

All patients with no risk of developing severe COVID-19 diseases.

symptom management, supportive care, and monitoring (at home, or in the community).

Control fevers with paracetamol, multivitamins and advise on balanced diet

Adults and Children >40kg at increased risk of de- veloping severe COVID-19 diseases. Refer to current Covid-19 treatment guidelines.

nimatrelvir/ritonavir 300/100mg orally (PO) twice daily for 5 days (must be initiated within 5 days of symptom onset)

OR remdesivir IV infusion Once daily for 3 days with a loading dose 200mg on Day 1 and 100mg on subsequent days. (initiated within 7 days of symptom onset)

OR molnupiravir 800mg orally (PO) twice daily for 5 days ONLY when ritonavir-boosted nirmatrelvir or remdesivir cannot be used; treatment should be initiated as soon as possible and within 5 days of symptom onset (contraindicated in pregnant or breastfeeding women and children)
 

If the patient requires hospitalization (Severe to Critical disease)

  • Oxygen therapy
  • And Corticosteroids
  • And Venous thromboembolism prophylaxis
  • And Interleukin-6 receptor blocker (tocilizumab or sarilumab) or JAK Inhibitor (baricitinib)

For details refer to the Comprehensive COVID-19 case Management Guidelines

 RR
Prevention
  • Vaccination (Refer to chapter 18: Immunization)
  • Epidemic preparedness i.e. prompt detection and treatment
  • Infection Prevention and control measures including Mask wearing, social distancing, regular handwashing, avoid shaking hands etc.